L. Odier

Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer

Ali Chour, Julie Denis, Céline Mascaux et al. · Journal of Thoracic Oncology · 2023 · 72 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting<i>ALK</i>and<i>ROS1</i>Fusion and Resistance Mutations in Patients With Non–Small-Cell Lung Cancer

Laura Mezquita, Aurélie Swalduz, Cécile Jovelet et al. · JCO Precision Oncology · 2020 · 49 citations · Full text

Medicine, Genetics, Oncology +17

Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors

K. Saboundji, J.B. Auliac, Maurice Pérol et al. · Targeted Oncology · 2018 · 43 citations

Medicine, Oncology, Pharmacology +16

Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort

Mateo Sanchis-Borja, Charles Ricordel, A Chiappa et al. · Lung Cancer · 2020 · 30 citations

Medicine, Immunology, Oncology +14

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study

Nicolas Girard, S. Galland-Girodet, Virginie Avrillon et al. · ESMO Open · 2022 · 15 citations · Full text

Medicine, Oncology, Pharmacology +16